文献速递关节外科创伤骨科

骨关节炎初次全肩关节置换:反式与解剖型全聚乙烯盂的翻修率比较

A Comparison of Revision Rates for Osteoarthritis of Primary Reverse Total Shoulder Arthroplasty to Primary Anatomic Shoulder Arthroplasty with a Cemented All-polyethylene Glenoid: Analysis from the Australian Orthopaedic Association National Joint Replacement Registry.
PubMed 文献 · Clin Orthop Relat Res · 2021-01-01

基于澳大利亚国家关节置换登记系统2015至2019年数据,比较3795例全聚乙烯盂解剖型全肩关节置换(aTSA)与8878例反式全肩关节置换(rTSA)治疗骨关节炎的翻修风险。调整年龄、性别、ASA评分和BMI后,4年累积翻修率两组无差异(aTSA 3.5% vs rTSA 3.0%),但rTSA术后3个月内翻修风险较高(HR 2.17),此后无差异;性别间翻修风险模式不同。

要点

  • 4年累积翻修率aTSA为3.5%,rTSA为3.0%,两组无差异。
  • rTSA术后3个月内翻修风险高于aTSA(HR 2.17,95%CI 1.25-3.70)。
  • 男性rTSA早期翻修风险更高,女性aTSA 3个月后翻修风险更高。

核心结论

  • rTSA与全聚乙烯盂aTSA治疗骨关节炎在4年生存率上无差异,但翻修风险存在性别差异。
  • 尽管rTSA当前更流行,术者仍可选择全聚乙烯盂aTSA治疗骨关节炎。

研究设计与样本

  • 比较性观察性登记研究,基于澳大利亚骨科协会国家关节置换登记系统2015年1月1日至2019年12月31日数据。
  • 纳入3795例全聚乙烯盂aTSA和8878例rTSA,均为骨关节炎初次置换。
  • 终点为全因翻修时间,采用Kaplan-Meier法和Cox比例风险模型调整年龄、性别、ASA评分和BMI。

主要发现

  • 4年累积翻修率aTSA为3.5%(95%CI 2.9%-4.2%),rTSA为3.0%(95%CI 2.6%-3.5%),总体无差异。
  • rTSA术后3个月内翻修风险高于aTSA(HR 2.17,95%CI 1.25-3.70,p=0.006),此后无差异。
  • 男性rTSA术后3个月内翻修风险高于aTSA(HR 4.0,95%CI 1.72-9.09,p=0.001),此后无差异。
  • 女性aTSA术后3个月起翻修风险高于rTSA(HR 2.77,95%CI 1.55-4.92,p<0.001),此前无差异。

关键数值与推荐

  • aTSA组平均年龄69±8岁,女性占56%;rTSA组平均年龄74±8岁,女性占61%。
  • aTSA组平均随访2.6±1.4年,rTSA组2.1±1.4年,最大随访5年。
  • ASA评分记录于12438例,BMI记录于11233例。

临床怎么用

  • 选择全聚乙烯盂aTSA或rTSA治疗骨关节炎时,4年翻修率无差异,可结合患者特征个体化决策。
  • 男性rTSA患者需关注术后3个月内早期翻修风险。
  • 女性aTSA患者需关注术后3个月后的翻修风险。

局限性

  • 观察性登记研究,存在未测量混杂因素可能。
  • 最大随访5年,缺乏长期生存率数据。
  • ASA评分和BMI存在缺失数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There has been decreased use of anatomic total shoulder arthroplasty (aTSA) because reverse TSA (rTSA) is increasingly being used for the same indications. Although short-term studies generally have not found survivorship differences between these implant designs, these studies are often small and their follow-up is limited to the short term. Likewise, the degree to which patient characteristics (such as gender, age, and American Society of Anesthesiologists [ASA] score) may or may not be associated with survivorship differences calls for larger and longer-term studies than is often possible in single-center designs. Large national registry studies may be able to help answer these questions. QUESTIONS/PURPOSES: By analyzing a large Australian registry series of primary aTSAs with cemented all-polyethylene glenoids and rTSA for osteoarthritis (OA), we asked: (1) Is the revision risk for OA higher for aTSA with all-polyethylene glenoids or for rTSA, adjusting for patient characteristics such as age, gender, ASA score, and BMI? (2) Is the patient's gender associated with differences in the revision risk after controlling for the potentially confounding factors of age, ASA score, and BMI? METHODS: In this comparative, observational registry study performed between January 1, 2015, and December 31, 2019, all primary aTSAs with all-polyethylene glenoids and rTSA for OA as determined by the treating surgeon and reported to our national registry formed two groups for analysis. The study period was set to time-match for the collection of ASA score and BMI in 2012 and 2015, respectively. Our registry enrolls more than 97% of all shoulder arthroplasties undertaken in Australia. There were 29,294 primary shoulder arthroplasties; 1592 hemiarthroplasties, 1876 resurfacing and stemless shoulders, 269 stemmed, and 11,674 reverse shoulder arthroplasties were excluded for other diagnoses. A total of 1210 metal-backed glenoids in stemmed aTSA for OA were excluded. A total of 3795 primary aTSAs with all-polyethylene glenoids and 8878 primary rTSAs for OA were compared. An aTSA with an all-polyethylene glenoid and rTSA were more likely to be performed in women (56% and 61% of patients, respectively). The mean age was 69 ± 8 years for aTSA with all-polyethylene glenoids and 74 ± 8 years for rTSA. One aTSA for OA was performed in a patient with an unknown glenoid type. The ASA score (n = 12,438) and BMI (n = 11,233) were also recorded. The maximum follow-up was 5 years for both groups, and the mean follow-up was 2.6 ± 1.4 years for aTSA with all-polyethylene glenoids and 2.1 ± 1.4 years for rTSA. The endpoint was time to revision (all causes), and the cumulative percent revision was determined using Kaplan-Meier estimates of survivorship (time to revision) and HRs from Cox proportional hazard models that were adjusted for age, gender, ASA score, and BMI category. RESULTS: Overall, there were no differences in the 4-year cumulative percent revision between the groups; the 4-year cumulative percent revision was 3.5% for aTSA with all-polyethylene glenoids (95% CI 2.9%-4.2%) and 3.0% for rTSA (95% CI 2.6%-3.5%). There was an increased risk of revision of rTSA compared with aTSA using all-polyethylene glenoids in the first 3 months (HR 2.17 [95% CI 1.25-3.70]; p = 0.006, adjusted for age, gender, ASA score, and BMI). After that time, there was no difference in the rate of revision, with the same adjustments. In the first 3 months, men undergoing rTSA had a higher rate of revision than men with aTSA using all-polyethylene glenoids (HR 4.0 [95% CI 1.72-9.09]; p = 0.001, adjusted for age, BMI, and ASA). There was no difference between men in the two groups after that time. Women with aTSA using all-polyethylene glenoids were at a greater risk of revision than women with rTSA from 3 months onward (HR 2.77 [95% CI 1.55-4.92]; p < 0.001, adjusted for age, BMI, and ASA), with no difference before that time. CONCLUSION: Given the absence of survivorship differences at 4 years between rTSA and aTSA, but in light of the differences in the revision risk between men and women, surgeons might select an aTSA with an all-polyethylene glenoid to treat OA, despite the current popularity of rTSA. However, there are survivorship differences between genders. Future studies should evaluate whether our comparative findings are replicated in men and women undergoing aTSA with all-polyethylene glenoids and rTSA for primary diagnoses such as rheumatoid arthritis or post-traumatic arthritis, and whether there are functional differences between the two implant designs when used for OA. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Gill DRJ, Page BMedSci RS, Graves SE, et al. A Comparison of Revision Rates for Osteoarthritis of Primary Reverse Total Shoulder Arthroplasty to Primary Anatomic Shoulder Arthroplasty with a Cemented All-polyethylene Glenoid: Analysis from the Australian Orthopaedic Association National Joint Replacement Registry. Clin Orthop Relat Res. 2021. PMID: 34180871. doi:10.1097/CORR.0000000000001869

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。